Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 2400 participants. Primary completion is estimated at 2033-03-23. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib. Registered primary measures: Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery; Event-Free Survival (EFS).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, TROP2, Early triple-negative breast cancer, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Epirubicin, Doxorubicin, Cyclophosphamide, Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, TROP2, Doxorubicin, Topoisomerase-I inhibitors (and ADC payloads) and the tag pipeline.
Shares Epirubicin, TROP2, Early triple-negative breast cancer, Doxorubicin and the tag pipeline.
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/